Journal of Neuro-Oncology

, Volume 51, Issue 3, pp 219–229

The INK4A/ARF Locus: Role in Cell Cycle Control and Apoptosis and Implications for Glioma Growth

  • Stacey M. Ivanchuk
  • Soma Mondal
  • Peter B. Dirks
  • James T. Rutka
Article

Abstract

The unique INK4A/ARF locus at chromosome 9p21 encodes two distinct proteins that intimately link the pRB and p53 tumour suppressor pathways. p16INK4A has been identified as an inhibitor of the cell cycle, capable of inducing arrest in G1 phase. p14/p19ARF on the other hand can induce both G1 and G2 arrest due to its stabilizing effects on the p53 transcription factor. In addition to their roles in growth arrest, both proteins are involved in cellular senescence and apoptosis. The frequent mutation or deletion of INK4A/ARF in human tumours as well as the occurence of tumours in the murine knockout models have identified both p16 and ARF as bona fide tumour suppressors.

apoptosis growth arrest INK4A/ARF p53 pRB tumour suppressor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323–30, 1995Google Scholar
  2. 2.
    Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323–31, 1997Google Scholar
  3. 3.
    Kamb A, GruisN A, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, 3rd, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436–40, 1994Google Scholar
  4. 4.
    Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704–7, 1993Google Scholar
  5. 5.
    Duro D, Bernard O, Della Valle V, Berger R, Larsen CJ: A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11: 21–9, 1995Google Scholar
  6. 6.
    Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D: A novel p16INK4A transcript. Cancer Res 55: 2995–7, 1995Google Scholar
  7. 7.
    Quelle DE, Ashmun RA, Hannon GJ, Rehberger PA, Trono D, Richter KH, Walker C, Beach D, Sherr CJ, Serrano M: Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene 11: 635–45, 1995Google Scholar
  8. 8.
    Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A: Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55: 2988–94, 1995Google Scholar
  9. 9.
    Zindy F, van Deursen J, Grosveld G, Sherr CJ, Roussel MF: INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol 20: 372–8, 2000Google Scholar
  10. 10.
    Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y: CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12: 2899–911, 1998Google Scholar
  11. 11.
    Roussel MF: The INK4 family of cell cycle inhibitors in cancer. Oncogene 18: 5311–7, 1999Google Scholar
  12. 12.
    Pavletich NP: Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287: 821–8, 1999Google Scholar
  13. 13.
    Koh J, Enders GH, Dynlacht BD, Harlow E:Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506–10, 1995Google Scholar
  14. 14.
    Noh SJ, Li Y, Xiong Y, Guan KL: Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6. Cancer Res 59: 558–64, 1999Google Scholar
  15. 15.
    McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G: Induced expression of p16(INK4a) inhibits both CDK4-and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol 19: 1981–9, 1999Google Scholar
  16. 16.
    Parry D, Bates S, Mann DJ, Peters G: Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. Embo J 14: 503–11, 1995Google Scholar
  17. 17.
    Parry D, Mahony D,Wills K, Lees E: CyclinD-CDKsubunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 19: 1775–83, 1999Google Scholar
  18. 18.
    Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP: Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395: 237–43, 1998Google Scholar
  19. 19.
    Brotherton DH, Dhanara V, Wick S, Brizuela L, Domaille PJ, Volyanik E, Xu X, Parisini E, Smith BO, Archer SJ: Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature 395: 244–50, 1998Google Scholar
  20. 20.
    Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375: 503–6, 1995Google Scholar
  21. 21.
    Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN: CDKN2/p16 or RB alterations occur in the ma ority of glioblastomas and are inversely correlated. Cancer Res 56: 150–3, 1996Google Scholar
  22. 22.
    Li Y, Nichols MA, Shay JW, Xiong Y: Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54: 6078–82, 1994Google Scholar
  23. 23.
    Shapiro GI, Edwards CD, Ewen ME, Rollins BJ: p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 18: 378–87, 1998Google Scholar
  24. 24.
    Liggett WH Jr, Sewell DA, Rocco J, Ahrendt SA, Koch W, Sidransky D: p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 56: 4119–23, 1996Google Scholar
  25. 25.
    Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ, Cavenee WK: Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway. Oncogene 15: 2013–20, 1997Google Scholar
  26. 26.
    Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D: Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1: 20–6, 1999Google Scholar
  27. 27.
    Tao W, Levine AJ: P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 96: 6937–41, 1999Google Scholar
  28. 28.
    Robertson KD, Jones PA: The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18: 6457–73, 1998Google Scholar
  29. 29.
    Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH: The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 17: 5001–14, 1998Google Scholar
  30. 30.
    Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993–1000, 1995Google Scholar
  31. 31.
    Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292–7, 1998Google Scholar
  32. 32.
    Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF: Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424–33, 1998Google Scholar
  33. 33.
    de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW: E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12: 2434–42, 1998Google Scholar
  34. 34.
    Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27–37, 1996Google Scholar
  35. 35.
    Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G: Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 16: 859–67, 1996Google Scholar
  36. 36.
    Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC: Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 93: 13742–7, 1996Google Scholar
  37. 37.
    Zindy F, Quelle DE, Roussel MF, Sherr CJ: Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15: 203–11, 1997Google Scholar
  38. 38.
    Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649–59, 1997Google Scholar
  39. 39.
    Uhrbom L, Nister M, Westermark B: Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene 15: 505–14, 1997Google Scholar
  40. 40.
    Stein GH, Drullinger LF, Soulard A, Dulic V: Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 19: 2109–17, 1999Google Scholar
  41. 41.
    Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW: Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593–602, 1997Google Scholar
  42. 42.
    Kamijo T, van de Kamp E, Chong MJ, Zindy F, Diehl JA, Sherr CJ, McKinnon PJ: Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res 59: 2464–9, 1999Google Scholar
  43. 43.
    Carnero A, Hudson JD, Price CM, Beach DH: p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2: 148–55, 2000Google Scholar
  44. 44.
    Schreiber M, Muller WJ, Singh G, Graham FL: Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 18: 1663–76, 1999Google Scholar
  45. 45.
    Kim M, Katayose Y, Rojanala L, Shah S, Sgagias M, Jang L, Jung YJ, Lee SH, Hwang SG, Cowan KH: Induction of apoptosis in p16INK4A mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein. Cell Death Differ 7: 706–711, 2000Google Scholar
  46. 46.
    Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL: Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658–69, 1999Google Scholar
  47. 47.
    Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW: INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13: 2670–7, 1999Google Scholar
  48. 48.
    Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Berkvig R, Yung WK, Sawaya R, Kyritsis AP, Rao JS: Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15: 2049–57, 1997Google Scholar
  49. 49.
    Fahraeus R, Lane DP: The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. Embo J 18: 2106–18, 1999Google Scholar
  50. 50.
    Marshall JF and Hart IR: The role of alpha v-integrins in tumour progression and metastasis. Semin Cancer Biol 7: 129–38, 1996Google Scholar
  51. 51.
    van Lookeren Campagne M, Gill R: Tumor-suppressor p53 is expressed in proliferating and newly formed neurons of the embryonic and postnatal rat brain: comparison with expression of the cell cycle regulators p21Waf1/Cip1, p27Kip1, p57Kip2, p16Ink4a, cyclin G1, and the proto-oncogene Bax. J Comp Neurol 397: 181–98, 1998Google Scholar
  52. 52.
    Watanabe G, Pena P, Shambaugh GE 3rd, Haines GK 3rd, Pestell RG: Regulation of cyclin dependent kinase inhibitor proteins during neonatal cerebella development. Brain Res Dev Brain Res 108: 77–87, 1998Google Scholar
  53. 53.
    Nielsen GP, Stemmer-Rachamimov AO, Shaw J, Roy JE, Koh J, Louis DN: Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest 79: 1137–43, 1999Google Scholar
  54. 54.
    Quelle DE, Cheng M, Ashmun RA, Sherr CJ: Cancerassociated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci USA 94: 669–73, 1997Google Scholar
  55. 55.
    Holland EC, Hively WP, DePinho RA, Varmus HE: Aconstitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12: 3675–85, 1998Google Scholar
  56. 56.
    Ruas M, Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115–77, 1998Google Scholar
  57. 57.
    Byeon IJ, Li J, Ericson K, Selby TL, Tevelev A, Kim HJ, O'Maille P, Tsai MD: Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase. Mol Cell 1: 421–31, 1998Google Scholar
  58. 58.
    Fitz Gerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ: Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 93: 8541–5, 1996Google Scholar
  59. 59.
    Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686–92, 1995Google Scholar
  60. 60.
    Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG: Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60: 129–33, 2000Google Scholar
  61. 61.
    Melendez B, Malumbres M, de Castro IP, Santos J, Pellicer A, Fernandez-Piqueras J: Characterization of the murine p19(ARF) promoter CpG island and its methylation pattern in primary lymphomas. Carcinogenesis 21: 817–21, 2000Google Scholar
  62. 62.
    Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353–8, 1994Google Scholar
  63. 63.
    Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the ma ority of glioblastomas. Cancer Res 54: 6321–4, 1994Google Scholar
  64. 64.
    He J, Olson JJ, James CD: Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55: 4833–6, 1995Google Scholar
  65. 65.
    Ichimura K, Schmidt EE, Goike HM, Collins VP: Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13: 1065–72, 1996Google Scholar
  66. 66.
    Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60: 417–24, 2000Google Scholar
  67. 67.
    Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG: p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19: 3816–22, 2000Google Scholar
  68. 68.
    Dirks PB, Patel K, Hubbard SL, Ackerley C, Hamel PA, Rutka JT: Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells. Oncogene 15: 2037–48, 1997Google Scholar
  69. 69.
    Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP: Adenovirusmediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12: 103–10, 1996Google Scholar
  70. 70.
    Costanzi-Strauss E, Strauss BE, Naviaux RK, Haas M: Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines. Exp Cell Res 238: 51–62, 1998Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Stacey M. Ivanchuk
    • 1
  • Soma Mondal
    • 1
  • Peter B. Dirks
    • 1
  • James T. Rutka
    • 1
  1. 1.Division of Neurosurgery and The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick ChildrenUniversity of TorontoTorontoCanada

Personalised recommendations